Literature DB >> 2856855

Adjuvant chemotherapy in stage II breast cancer: a brief overview of the NSABP clinical trials.

N Wolmark, B Fisher.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2856855     DOI： 10.1007/bf01655183

Source DB:  PubMed          Journal:  World J Surg        ISSN： 0364-2313            Impact factor:   3.352


× No keyword cloud information.
  6 in total

1.  Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation.

Authors:  B Fisher; R G Ravdin; R K Ausman; N H Slack; G E Moore; R J Noer
Journal:  Ann Surg       Date:  1968-09       Impact factor: 12.969

2.  Combination cytotoxic chemotherapy in advanced disseminated breast carcinoma.

Authors:  E M Greenspan
Journal:  J Mt Sinai Hosp N Y       Date:  1966 Jan-Feb

3.  1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings.

Authors:  B Fisher; P Carbone; S G Economou; R Frelick; A Glass; H Lerner; C Redmond; M Zelen; P Band; D L Katrych; N Wolmark; E R Fisher
Journal:  N Engl J Med       Date:  1975-01-16       Impact factor: 91.245

4.  Dose-response effect of adjuvant chemotherapy in breast cancer.

Authors:  G Bonadonna; P Valagussa
Journal:  N Engl J Med       Date:  1981-01-01       Impact factor: 91.245

5.  L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. An update of earlier findings and a comparison with those utilizing L-PAM plus 5-fluorouracil (5-FU).

Authors:  B Fisher; A Glass; C Redmond; E R Fisher; B Barton; E Such; P Carbone; S Economou; R Foster; R Frelick; H Lerner; M Levitt; R Margolese; J MacFarlane; D Plotkin; H Shibata; H Volk
Journal:  Cancer       Date:  1977-06       Impact factor: 6.860

6.  The contribution of recent NSABP clinical trials of primary breast cancer therapy to an understanding of tumor biology--an overview of findings.

Authors:  B Fisher; C Redmond; E R Fisher
Journal:  Cancer       Date:  1980-08-15       Impact factor: 6.860
  6 in total
  1 in total

1.  Postmenopausal patients with node-positive resectable breast cancer. Tamoxifen vs FEC 50 (6 cycles) vs FEC 50 (6 cycles) plus tamoxifen vs control--preliminary results of a 4-arm randomised trial. The French Adjuvant Study Group.

Authors:  J P Gérard; M Héry; D Gedouin; A Monnier; M J Goudier; J P Jacquin; F Plat; E Cabarrot; D Serin; M Namer
Journal:  Drugs       Date:  1993       Impact factor: 9.546
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.